LIVIVO - Search results -

Search results

Result 1 - 10 of total 79

Search options

Book: Myelodysplastische Syndrome von A bis Z

Gattermann, Norbert / Giagounidis, Aristoteles / Haferlach, Torsten

2021

Author's details	herausgegeben von Torsten Haferlach ; unter Mitarbeit von Norbert Gattermann, Aristoteles Giagounidis
Keywords	Myelodysplastisches Syndrom
Subject	MDS ; Präleukämie ; Präleukose ; Präleukämisches Syndrom ; Hämatopoetische Dysplasie
Language	German
Size	IX, 130 Seiten, 41 Illustrationen
Edition	4. Auflage
Publisher	Georg Thieme Verlag
Publishing place	Stuttgart ; New York
Publishing country	Germany
Document type	Book
Old title	Vorangegangen ist
HBZ-ID	HT020702834
ISBN	978-3-13-243228-4 ; 3-13-243228-8
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2021 A 415	available for loan (reading room)	Lesesaal EG

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.

Giagounidis, Aristoteles A N

Seminars in hematology

2012 Volume 49, Issue 4, Page(s) 312–322

Abstract: Lenalidomide leads to high rates of erythroid transfusion independence in low and intermediate-1 risk International Prognostic Scoring System (IPSS) del(5q) myelodysplastic syndromes (MDS), with a considerable number of patients achieving complete and ... ...

Abstract	Lenalidomide leads to high rates of erythroid transfusion independence in low and intermediate-1 risk International Prognostic Scoring System (IPSS) del(5q) myelodysplastic syndromes (MDS), with a considerable number of patients achieving complete and partial cytogenetic remissions. The median duration of transfusion independence is 2 years, mainly at the expense of neutropenia and thrombocytopenia in the first courses of therapy. At present, the optimal initial treatment dose has been determined to be 10 mg administered orally daily for 21 out of 28 days. In general, the effects in non-del(5q) disease can be divided by 50%: non-del(5q) patients show 50% of erythroid response, 50% of duration of response, and 50% incidence of grade 3 and 4 neutropenia and thrombocytopenia compared to del(5q) patients. Recent data suggest that the risk of acute myeloid leukemia (AML) progression of del(5q) patients is dependent on their individual risk factors before treatment initiation, including World Health Organization (WHO) prognostic scoring system parameters and TP53 mutations. These data also indicate that lenalidomide per se is not leukemogenic. Length of treatment can be tailored according to response, and patients who relapse during treatment might restart after a period of drug holiday. This article will also discuss combination strategies with lenalidomide in higher risk disease.
MeSH term(s)	Chromosome Deletion ; Chromosomes, Human, Pair 5 ; Humans ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/genetics ; Thalidomide/analogs & derivatives ; Thalidomide/pharmacology ; Thalidomide/therapeutic use ; Treatment Outcome
Chemical Substances	Thalidomide (4Z8R6ORS6L) ; lenalidomide (F0P408N6V4)
Language	English
Publishing date	2012-10
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	206923-4
ISSN	1532-8686 ; 0037-1963
ISSN (online)	1532-8686
ISSN	0037-1963
DOI	10.1053/j.seminhematol.2012.07.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 328: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network.

Fischer, Luca / Jiang, Linmiao / Dürig, Jan / Schmidt, Christian / Stilgenbauer, Stephan / Bouabdallah, Krimo / Solal-Celigny, Philippe / Scholz, Christian W / Feugier, Pierre / de Wit, Maike / Trappe, Ralf Ulrich / Hallek, Michael / Graeven, Ullrich / Hänel, Mathias / Hoffmann, Martin / Delwail, Vincent / Macro, Margaret / Greiner, Jochen / Giagounidis, Aristoteles A N /

Dargel, Beate / Durot, Eric / Foussard, Charles / Silkenstedt, Elisabeth / Weigert, Oliver / Pott, Christiane / Klapper, Wolfram / Hiddemann, Wolfgang / Unterhalt, Michael / Hoster, Eva / Ribrag, Vincent / Dreyling, Martin

Leukemia

2024

Abstract: ... n = 64) or R-HAD (n = 64). Median TTF was 12 vs. 2.6 months (p = 0.045, MIPI-adjusted HR 0.69; 95%CI ...

Abstract	The therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted a randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy of rituximab, high-dose cytarabine and dexamethasone with bortezomib (R-HAD + B) versus without (R-HAD) in r/r MCL ineligible for or relapsed after autologous stem cell transplant (ASCT). Primary endpoint was time to treatment failure (TTF), secondary endpoints included response rates, progression free survival, overall survival, and safety. In total, 128 of 175 planned patients were randomized to R-HAD + B (n = 64) or R-HAD (n = 64). Median TTF was 12 vs. 2.6 months (p = 0.045, MIPI-adjusted HR 0.69; 95%CI 0.47-1.02). Overall and complete response rates were 63 vs. 45% (p = 0.049) and 42 vs. 19% (p = 0.0062). A significant treatment effect was seen in the subgroup of patients >65 years (aHR 0.48, 0.29-0.79) and without previous ASCT (aHR 0.52, 0.28-0.96). Toxicity was mostly hematological and attributable to the chemotherapeutic backbone. Grade ≥3 leukocytopenia and lymphocytopenia were more common in R-HAD + B without differences in severe infections between both arms. Bortezomib in combination with chemotherapy can be effective in r/r MCL and should be evaluated further as a therapeutic option, especially if therapy with BTK inhibitors is not an option. Trial registration: NCT01449344.
Language	English
Publishing date	2024-04-27
Publishing country	England
Document type	Journal Article
ZDB-ID	807030-1
ISSN	1476-5551 ; 0887-6924
ISSN (online)	1476-5551
ISSN	0887-6924
DOI	10.1038/s41375-024-02254-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2295: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Decitabine dosage in myelodysplastic syndromes.

Giagounidis, Aristoteles A N

Blood

2007 Volume 110, Issue 3, Page(s) 1082–3; author reply 1083

MeSH term(s)	Aged ; Antimetabolites, Antineoplastic/administration & dosage ; Antimetabolites, Antineoplastic/adverse effects ; Azacitidine/administration & dosage ; Azacitidine/adverse effects ; Azacitidine/analogs & derivatives ; Decitabine ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Infusions, Intravenous ; Injections, Subcutaneous ; Leukemia, Myelomonocytic, Chronic/drug therapy ; Male ; Middle Aged ; Myelodysplastic Syndromes/drug therapy ; Randomized Controlled Trials as Topic ; Remission Induction ; Treatment Outcome
Chemical Substances	Antimetabolites, Antineoplastic ; Decitabine (776B62CQ27) ; Azacitidine (M801H13NRU)
Language	English
Publishing date	2007-07-20
Publishing country	United States
Document type	Letter ; Comment
ZDB-ID	80069-7
ISSN	1528-0020 ; 0006-4971
ISSN (online)	1528-0020
ISSN	0006-4971
DOI	10.1182/blood-2007-03-080903
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.140: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 364: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center.

Nachtkamp, Kathrin / Stark, Josefine / Kündgen, Andrea / Schroeder, Thomas / Strupp, Corinna / Strapatsas, Judith / Schuler, Esther / Kaivers, Jennifer / Giagounidis, Aristoteles / Rautenberg, Christina / Aul, Carlo / Runde, Volker / Haas, Rainer / Kobbe, Guido / Gattermann, Norbert / Germing, Ulrich

Leukemia research

2021 Volume 108, Page(s) 106611

Abstract: ... participation. The simulation also posited that all MDS trials (n = 47) conducted in our center between 1987 and ...

Abstract	Participation in clinical trials may allow patients with MDS to gain access to therapies not otherwise available. However, access is limited by strict inclusion and exclusion criteria, reflecting academic or regulatory questions addressed by the respective studies. We performed a simulation in order to estimate the average proportion of MDS patients eligible for participation in a clinical trial. The simulation drew upon 1809 patients in the Düsseldorf MDS Registry whose clinical data allowed eligibility screening for a wide range of clinical trials. This cohort was assumed to be alive and available for study participation. The simulation also posited that all MDS trials (n = 47) conducted in our center between 1987 and 2016 were open for recruitment. In addition, study activities in the year 2016 were analyzed to determine the proportion of patients eligible for at least one of the 9 MDS trials open at that time. On average, each clinical trial was suitable for about 18 % of patients in the simulation cohort. Conversely, 34 % of the patients were eligible for at least one of the 9 clinical studies in 2016. Inclusion/exclusion criteria of studies initiated by the pharmaceutical industry excluded more than twice the fraction of patients compared with investigator initiated trials (potential inclusion of 10 % vs. 21 %, respectively). Karyotype (average exclusion rate 58 %), comorbidities (40 %), and prior therapies (55 %) were the main reasons for exclusion. We suggest that in- and exclusion criteria should be less restrictive, in order to meet the needs of the real-life population of elderly MDS patients.
Language	English
Publishing date	2021-05-11
Publishing country	England
Document type	Journal Article
ZDB-ID	752396-8
ISSN	1873-5835 ; 0145-2126
ISSN (online)	1873-5835
ISSN	0145-2126
DOI	10.1016/j.leukres.2021.106611
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1321: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Treatment of Combined Autoimmune Neutropenia and Immune Thrombocytopenia with Methotrexate.

Mitsogianni, Maria / Mitsimponas, Nikolaos / Haase, Sabine / Giagounidis, Aristoteles

Acta haematologica

2019 Volume 143, Issue 1, Page(s) 89–90

MeSH term(s)	Adult ; Antimetabolites, Antineoplastic/therapeutic use ; Autoantibodies/blood ; Autoimmune Diseases/complications ; Autoimmune Diseases/diagnosis ; Autoimmune Diseases/drug therapy ; Humans ; Male ; Methotrexate/therapeutic use ; Neutropenia/complications ; Neutropenia/diagnosis ; Neutrophils/cytology ; Platelet Count ; Thrombocytopenia/complications ; Thrombocytopenia/diagnosis ; Thrombocytopenia/immunology
Chemical Substances	Antimetabolites, Antineoplastic ; Autoantibodies ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2019-06-28
Publishing country	Switzerland
Document type	Letter
ZDB-ID	80008-9
ISSN	1421-9662 ; 0001-5792
ISSN (online)	1421-9662
ISSN	0001-5792
DOI	10.1159/000500872
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ud II Zs.145: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The 5q- syndrome.

Giagounidis, Aristoteles A N / Aul, Carlo

Cancer treatment and research

2008 Volume 142, Page(s) 133–148

MeSH term(s)	Chromosome Deletion ; Chromosome Disorders ; Chromosomes, Human, Pair 5 ; Clinical Trials as Topic ; Humans ; Myelodysplastic Syndromes/genetics
Language	English
Publishing date	2008
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ISSN	0927-3042
ISSN	0927-3042
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results from the LenaMain Trial (NCT00891384).

Boquoi, Amelie / Giagounidis, Aristoteles / Goldschmidt, Hartmut / Heinsch, Michael / Rummel, Mathias J / Kröger, Nicolaus / Mai, Elias K / Strapatsas, Judith / Haas, Rainer / Kobbe, Guido

Cancers

2023 Volume 15, Issue 21

Abstract: Introduction: The LenaMain trial (NCT00891384) reported increased progression-free survival with 25 mg of lenalidomide maintenance compared to 5 mg. Here, we report the patient-reported outcomes.: Materials and methods: Scores obtained from the EORTC ...

Abstract	Introduction: The LenaMain trial (NCT00891384) reported increased progression-free survival with 25 mg of lenalidomide maintenance compared to 5 mg. Here, we report the patient-reported outcomes. Materials and methods: Scores obtained from the EORTC Quality of Life Questionnaire C30 were analyzed for longitudinal changes from baseline within the groups as well as cross-sectional scores. Results: Compliance rates were high, with 95.7% at baseline and 70% during maintenance. At study entry, scores were high for functioning and low for symptoms. During maintenance, the median global health status/quality of life (GHS/QoL) was constant, without significant differences over time (median GHS/QoL: 68 at baseline and 58 for Len high and 68 for Len low at 2 years) and between treatment arms (mean change < 2). Similarly, most functional scale domains were constant. Notably, diarrhea increased consistently for both treatment arms (baseline: -1.905 (range: -5.78-1.97); end of year 2: 16.071 (range: 5.72-26.42); Conclusion: High baseline scores were maintained throughout the trial without significant differences between the Len dosages, which supports continuous treatment with a dose tailored to patients' HR-QoL.
Language	English
Publishing date	2023-10-26
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers15215157
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.

Itzykson, Raphael / Santini, Valeria / Thepot, Sylvain / Ades, Lionel / Chaffaut, Cendrine / Giagounidis, Aristoteles / Morabito, Margot / Droin, Nathalie / Lübbert, Michael / Sapena, Rosa / Nimubona, Stanislas / Goasguen, Jean / Wattel, Eric / Zini, Gina / Torregrosa Diaz, Jose Miguel / Germing, Ulrich / Pelizzari, Anna Maria / Park, Sophie / Jaekel, Nadja /

Metzgeroth, Georgia / Onida, Francesco / Navarro, Robert / Patriarca, Andrea / Stamatoullas, Aspasia / Götze, Katharina / Puttrich, Martin / Mossuto, Sandra / Solary, Eric / Gloaguen, Silke / Chevret, Sylvie / Chermat, Fatiha / Platzbecker, Uwe / Fenaux, Pierre

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

2022 Volume 41, Issue 10, Page(s) 1888–1897

Abstract: ... received DAC (n = 84) or HY (n = 86). Median age was 72 and 74 years, and median WBC count 32.5 × 10 ...

Abstract	Purpose: Hydroxyurea (HY) is a reference treatment of advanced myeloproliferative neoplasms. We conducted a randomized phase III trial comparing decitabine (DAC) and HY in advanced myeloproliferative chronic myelomonocytic leukemias (CMML). Patients and methods: Newly diagnosed myeloproliferative CMML patients with advanced disease were randomly assigned 1:1 to intravenous DAC (20 mg/m Results: One-hundred seventy patients received DAC (n = 84) or HY (n = 86). Median age was 72 and 74 years, and median WBC count 32.5 × 10 Conclusion: Compared with HY, frontline treatment with DAC did not improve EFS in patients with advanced myeloproliferative CMML (ClinicalTrials.gov identifier: NCT02214407).
MeSH term(s)	Humans ; Aged ; Leukemia, Myelomonocytic, Chronic/drug therapy ; Leukemia, Myelomonocytic, Chronic/diagnosis ; Decitabine ; Hydroxyurea/adverse effects ; Leukemia, Myelomonocytic, Acute/drug therapy ; Proportional Hazards Models
Chemical Substances	Decitabine (776B62CQ27) ; Hydroxyurea (X6Q56QN5QC)
Language	English
Publishing date	2022-12-01
Publishing country	United States
Document type	Randomized Controlled Trial ; Clinical Trial, Phase III ; Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	604914-x
ISSN	1527-7755 ; 0732-183X
ISSN (online)	1527-7755
ISSN	0732-183X
DOI	10.1200/JCO.22.00437
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1847: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 650: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).

Hecht, Anna / Meyer, Julia A / Jann, Johann-Christoph / Sockel, Katja / Giagounidis, Aristoteles / Götze, Katharina S / Letsch, Anne / Haase, Detlef / Schlenk, Richard F / Haferlach, Torsten / Schafhausen, Philippe / Bug, Gesine / Lübbert, Michael / Thol, Felicitas / Büsche, Guntram / Schuler, Esther / Nowak, Verena / Obländer, Julia / Fey, Stephanie /

Müller, Nadine / Metzgeroth, Georgia / Hofmann, Wolf-Karsten / Germing, Ulrich / Nolte, Florian / Reinwald, Mark / Nowak, Daniel

Annals of hematology

2021 Volume 100, Issue 6, Page(s) 1463–1471

Abstract: ... arrays was performed on n=51 patients with MDS del5q who were uniformly treated with lenalidomide ...

Abstract	Myelodysplastic syndrome (MDS) with isolated deletion of chromosome 5q (MDS del5q) is a distinct subtype of MDS with quite favorable prognosis and excellent response to treatment with lenalidomide. Still, a relevant percentage of patients do not respond to lenalidomide and even experience progression to acute myeloid leukemia (AML). In this study, we aimed to investigate whether global DNA methylation patterns could predict response to lenalidomide. Genome-wide DNA methylation analysis using Illumina 450k methylation arrays was performed on n=51 patients with MDS del5q who were uniformly treated with lenalidomide in a prospective multicenter trial of the German MDS study group. To study potential direct effects of lenalidomide on DNA methylation, 17 paired samples pre- and post-treatment were analyzed. Our results revealed no relevant effect of lenalidomide on methylation status. Furthermore, methylation patterns prior to therapy could not predict lenalidomide response. However, methylation clustering identified a group of patients with a trend towards inferior overall survival. These patients showed hypermethylation of several interesting target genes, including genes of relevant signaling pathways, potentially indicating the evaluation of novel therapeutic targets.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Chromosome Deletion ; Chromosomes, Human, Pair 5/genetics ; DNA Methylation/drug effects ; Female ; Humans ; Lenalidomide/pharmacology ; Lenalidomide/therapeutic use ; Male ; Middle Aged ; Myelodysplastic Syndromes/drug therapy ; Myelodysplastic Syndromes/genetics ; Treatment Outcome
Chemical Substances	Antineoplastic Agents ; Lenalidomide (F0P408N6V4)
Language	English
Publishing date	2021-04-27
Publishing country	Germany
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study
ZDB-ID	1064950-5
ISSN	1432-0584 ; 0939-5555 ; 0945-8077
ISSN (online)	1432-0584
ISSN	0939-5555 ; 0945-8077
DOI	10.1007/s00277-021-04492-1
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.181: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito